Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors Clinical research trials and Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors. Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors clinical trial. Participants oftentimes recieve the most expert healthcare available for their Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors

Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors



Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors

For Condition: childhood brain tumor,childhood meningioma
Status: Recruiting
Sponsor(s): Burzynski Research Institute ,
Synopsis: RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. PURPOSE: This phase II trial studies the effectiveness of antineoplaston therapy in treating children who have primarymalignant brain tumors.
Details: OBJECTIVES: - Determine the antitumor activity of antineoplastons A10 and AS2-1 in children with primary malignant brain tumors by determining the proportion of patients who experience an objective tumor response. - Evaluate the adverse effects of and tolerance to this regimen in these children. OUTLINE: This is an open-label study. Patients receive gradually escalating doses of intravenous antineoplaston A10 and antineoplaston AS2-1 6 times daily until the maximum tolerated dose is reached. Treatment continues for at least 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients with responding or stable disease may continue treatment. Tumors are measured every 8 weeks for 2 years, every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study.
Eligibility:
Study Type:  Interventional, Treatment
Minimum Age/Maximum Age: /18 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed incurable primary malignant brain tumor that has progressed, recurred, or persisted after initial therapy - Must have failed prior standard therapy - No brain stem glioma - Evidence of tumor by MRI or CT scan PATIENT CHARACTERISTICS: Age: - 6 months to 18 years Performance status: - Karnofsky 60-100% Life expectancy: - At least 2 months Hematopoietic: - WBC at least 1,500/mm^3 - Platelet count greater than 50,000/mm^3 Hepatic: - No hepatic failure - Bilirubin no greater than 2.5 mg/dL - SGOT/SGPT no greater than 5 times upper limit of normal Renal: - Creatinine no greater than 2.5 mg/dL Cardiovascular: - No severe heart disease - No uncontrolled hypertension Pulmonary: - No severe lung disease Other: - Not pregnant or nursing - Fertile patients must use effective contraception during and for 4 weeks after study participation - No serious active infections or fever - No other serious concurrent disease PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 4 weeks since prior immunotherapy and recovered - No concurrent immunomodulating agents Chemotherapy: - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered - No concurrent antineoplastic agents Endocrine therapy: - Recovered from prior endocrine therapy - Concurrent corticosteroids for cerebral edema allowed Radiotherapy: - At least 8 weeks since prior radiotherapy (unless clear radiological evidence of progression) and recovered Surgery: - At least 4 weeks since prior surgery (unless clear radiological evidence of progression) and recovered Other: - No prior antineoplaston therapy
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
StanislawBurzynski,  Study Chair,  Burzynski Research Institute

Burzynski Clinic *Recruiting*
Houston,  Texas,  77055-6330
United States
Recruiting Stanislaw  Burzynski 713-335-5697


Additional Information:
Study ID Numbers:  CDR0000066513;  BC-BT-22
Study Start Date: 
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003476

Other Childhood Brain Tumor Studies:
1. Antineoplaston Therapy in Treating Children With Brain Tumors

2. Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment

3. Chemotherapy and Stem Cell Transplantation in Treating Children with Central Nervous System Cancer

4. Temozolomide in Treating Patients With Progressive Low-Grade Glioma

5. DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

Related Studies:

Other childhood brain tumor Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials

Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors
Modify your Search

  Other childhood brain tumor Clinical Trials
  Other Texas Clinical Trials
  Other Houston Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103